Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion

Aim: to present the results of an expert discussion of modern aspects of the clinical manifestations, pathogenesis and treatment of alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD).

Key points. ALD and NAFLD are characterized by high prevalence and have a significant impact on public health. For the diagnosis of liver pathology, it is important to determine the stage of fibrosis and the severity of the exacerbation of the disease. In the treatment of ALD, it is recommended to achieve abstinence, proper nutrition, the appointment of B vitamins, drugs with cytoprotective activity. In severe hepatitis, corticosteroids may be prescribed. In the treatment of NAFLD, diet and lifestyle modification, weight loss, the use of insulin sensitizers, vitamin E, statins (in the presence of hyperlipidemia) and drugs with metabolic activity are effective.

Currently, a point of view is being actively expressed about the synergism of the action of alcohol and the metabolic syndrome on the development of fibrosis, cirrhosis, and hepatocellular carcinoma. The current international consensus recommends a change in the nomenclature of NAFLD and ALD and proposes the terms “metabolically associated steatotic liver disease” and “metabolically associated alcoholic liver disease”.

Conclusion. The closeness of the clinical manifestations and pathogenesis of NAFLD and ALD justifies attention to drugs with metabolic activity, which are recommended by the Russian Gastroenterological Association and Russian Scientific Liver Society for the treatment of these diseases. The experts support the suggestion to quantify alcohol consumption in patients with NAFLD in order to change the management of patients, if necessary.

1. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434-438.

2. Lieber C.S. Alcohol and the liver: 1984 update. Hepatology. 1984;4(6):1243-1260. https://doi.org/10.1002/hep.1840040625

3. Eslam M., Newsome P.N., Sarin S.K., Anstee Q.M., Targher G., Romero-Gomez M., et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-209. https://doi.org/10.1016/j.jhep.2020.03.039

4. Tkachenko P., Maevskaya M., Pavlov A., Komkova I., Pavlov C., Ivashkin V. Prednisolone plus S-adenosil-L-methionine in severe alcoholic hepatitis. Hepatol Int. 2016;10(6):983-987. https://doi.org/10.1007/s12072-016-9751-4

5. Mato J.M., Cámara J., Fernández de Paz J., Caballería L., Coll S., Caballero A., et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30(6):1081-1089. https://doi.org/10.1016/s0168-8278(99)80263-3

6. Staufer K., Mangal B., Trauner M. Detection of unreported alcohol consumption in fatty liver disease. J Hepatol. 2023;78(2):e67-e69. https://doi.org/10.1016/j.jhep.2022.10.016

7. Pascale R.M., Simile M.M., Calvisi D.F., Feo C.F., Feo F. S-Adenosylmethionine: From the Discovery of Its Inhibition of Tumorigenesis to Its Use as a Therapeutic Agent. Cells. 2022;11(3):409. https://doi.org/10.3390/cells11030409

8. Noureddin M., Sander-Struckmeier S., Mato J.M. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. World J Hepatol. 2020;12(2):46-63. https://doi.org/10.4254/wjh.v12.i2.46

9. Murphy S.K., Yang H., Moylan C.A., Pang H., Dellinger A., Abdelmalek M.F., et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145(5):1076-1087. https://doi.org/10.1053/j.gastro.2013.07.047

10. Baranovsky AYu, Raykhelson KL, Marchenko NV. Application of S-adenosylmethionine (Heptral®) in treatment of patients with non-alcoholic steatohepatitis. Klinicheskie Perspektivy Gastroenterologii, Gepatologii = Clin Perspect Gastroenterol Hepatol. 2010;9(1):3-10. (In Russ.)

11. Younossi Z.M., Stepanova M., Ong J., Yilmaz Y., Duseja A., Eguchi Y., et al. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019;17(8):1625-1633. https://doi.org/10.1016/j.cgh.2018.11.033

12. Åberg F., Byrne C.D., Pirola C.J., Männistö V., Sookoian S. Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease. J Hepatol. 2023;78(1):191-206. https://doi.org/10.1016/j.jhep.2022.08.030

13. Crabb D.W., Im G.Y., Szabo G., Mellinger J.L., Lucey M.R. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American association for the study of liver diseases. Hepatology, 2020;71:306–333. https://doi.org/10.1002/hep.30866

14. Roerecke M., Vafaei A., Hasan O.S.M., Chrystoja B.R., Cruz M., Lee R., et al. Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis. Am J Gastroenterol. 2019;114(10):1574–1586. https://doi.org/10.14309/ajg.0000000000000340

15. Long M.T., Zhang X., Xu H., Liu C-T., Corey K.E., Chung R.T., et al. Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: the framingham heart study. Hepatology. 2021;73(2):548–559. https://doi.org/10.1002/hep.31608

16. Welzel T.M., Graubard B.I., Zeuzem S., El-Serag H.B., Davila J.A., McGlynn K.A. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54(2):463–471. https://doi.org/10.1002/hep.24397

17. Ren H., Wang J., Gao Y., Yang F., Huang W. Metabolic syndrome and liverrelated events: a systematic review and meta-analysis. BMC Endocr Disord. 2019;19(1):40. https://doi.org/10.1186/s12902-019-0366-3

18. Knott C., Bell S., Britton A. Alcohol consumption and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis of more than 1.9 million individuals from 38 observational studies. Diabetes Care. 2015;38(9):1804–1812. https://doi.org/10.2337/dc15-0710

19. Åberg F., Färkkilä M., Männistö V. Interaction between alcohol use and metabolic risk factors for liver disease: a critical review of epidemiological studies. Alcohol Clin Exp Res. 2020;44(2):384–403. https://doi.org/10.1111/acer.14271

20. Boyle M., Masson S., Anstee Q.M. The bidirectional impacts of alcohol consumption and the metabolic syndrome: cofactors for progressive fatty liver disease. J Hepatol. 2018;68(2):251–267. https://doi.org/10.1016/j.jhep.2017.11.006

21. Jamialahmadi O., Mancina R.M., Ciociola E., Tavaglione F., Luukkonen P.K., Baselli G., et al. Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease. Gastroenterology 2021;160(5):1634–1646.e7. https://doi.org/101053/j.gastro.2020.12.023

22. Li S., Tan H-Y., Wang N., Feng Y., Wang X., Feng Y.. Recent insights into the role of immune cells in alcoholic liver disease. Front Immunol. 2019;10:1328. https://doi.org/10.3389/fimmu.2019.01328

23. Ramos-Tovar E., Muriel P. Molecular mechanisms that link oxidative stress, inflammation, and fibrosis in the liver. Antioxidants (Basel) 2020;9(12):1279. https://doi.org/10.3390/antiox9121279

24. Lemmer P., Manka P., Best J., Kahraman A., Kälsch J., Vilchez-Vargas R., et al. Effects of moderate alcohol consumption in non-alcoholic fatty liver disease. J Clin Med 2022;11(3):890. https://doi.org/10.3390/jcm11030890

25. Idalsoaga F., Kulkarni A.V., Mousa O.Y., Arrese M., Arab J.P.. Non-alcoholic fatty liver disease and alcohol-related liver disease: two intertwined entities. Front Med (Lausanne). 2020;7:448. https://doi.org/10.3389/fmed.2020.00448

26. Rinella M.E., Neuschwander-Tetri B.A., Siddiqui M.S., Abdelmalek M.F., Caldwell S., Barb D., et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. https://doi.org/10.1097/HEP.0000000000000323

27. Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F., et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023:S0168-8278(23)00418-X. https://doi.org/10.1016/j.jhep.2023.06.003 (Online ahead of print)

28. Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Kotovskaya Yu.V., Tkacheva O.N., Troshina E.A., et al. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):104-140. https://doi.org/10.22416/1382-4376-2022-32-4-104-140 (In Russ.)

29. Ivashkin V.T., Mayevskaya M.V., Pavlov Ch.S., Sivolap Yu.P., Lunkov V.D., Zharkova M.S., et al. Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society. Ross z gastroenterol gepatol koloproktol 2017; 27(6):20-40. https://doi.org/10.22416/1382-4376-2017-27-6-20-40 (In Russ.)